Editor's Note Patients prescribed a glucagon-like peptide-1 agonist (GLP-1) showed higher postoperative infection rates after ankle-fusion procedures in a study presented at the annual meeting of the American Orthopaedic Foot & Ankle Society. Healio reported the news September 20.   Conducted by a team at the Milton S. Hershey Medical…

Read More

Editor's Note Findings to be presented at the American Heart Association's Hypertension Scientific Sessions 2024 suggest bariatric surgery may offer more effective long-term control of high blood pressure for people with obesity compared to medications and lifestyle changes, according to a September 5 report in News Medical. According to the…

Read More

Editor's Note A shuttered bariatric surgery center in Oklahoma last month is just one example of how the rise of Glucagon-like peptide-1 (GLP-1) agonists are reshaping health systems’ investments, Axios reported August 13. Rather than “massive hospital towers with cardiology clinics, dialysis beds and joint replacement centers,” the focus is…

Read More

Editor's Note For diabetic patients with obesity and chronic kidney disease (CKD), metabolic bariatric surgery could protect the kidneys better than therapy with glucagon-like peptide-1 receptor agonists (GLP-1RA), according to research published in the September issue of the Annals of Surgery. Conducted at a large US health system, the study…

Read More

Editor's Note Healthcare costs are expected to rise between 7% and 8% in 2025, according to a report from PwC's Health Research Institute. As detailed in a July 17 article from Fierce Healthcare, PwC projections for an 8% increase in the group market and 7.5% in the individual market would…

Read More

Editor's Note Roux-en-Y gastric bypass surgery kept type 2 diabetes in remission for up to 15 years and maintained most of the weight loss for up to 20 years in a long-term study, according to a June 12 report in SciTech Daily. Presented the same day at The American Society…

Read More

Editor's Note Bariatric surgery provides longer-lasting, more effective weight loss than GLP-1 receptor agonists and lifestyle interventions, according to systematic reviews of medical literature from 2020 to 2024. Medical Xpress reported the news June 11. Presented at the American Society for Metabolic and Bariatric Surgery (ASMBS) 2024 Annual Scientific Meeting,…

Read More

Editor's Note Preoperative use of GLP-1 receptor agonists (RA) medications such as Ozempic and Wegovy is safe, according to a study published in the June issue of the American Journal of Gastroenterology. Controversy has swirled around these drugs due to the risk of slowed stomach emptying increasing a patient’s odds…

Read More

Editor's Note Semaglutide, the active ingredient in Ozempic diabetes treatment and Wegovy weight-loss treatment, outperformed a placebo and demonstrated capacity to reduce risk of death from kidney-related or cardiovascular causes in a recent study of patients with type 2 diabetes and chronic kidney disease spearheaded by manufacturer Novo Nordisk. Published…

Read More

Editor's Note Popular weight-loss \ drug semaglutide could significantly increase risk for repeat operations patients with diabetes who undergo lumbar surgery. According to a May 8 report in Medscape Medical News, the findings are pending review for publication and reportedly provides the first evidence on the impact of semaglutide on…

Read More